Navigation Links
Popular Alzheimer's theory may be false trail

GAINESVILLE, Fla. The idea that anti-inflammatory drugs might protect people struggling with dementia from Alzheimer's disease has received a blow with the online release of a study of human brain tissue in Acta Neuropathologica.

Researchers with the McKnight Brain Institute of the University of Florida, in collaboration with scientists at the University of Frankfurt, Germany, discovered that inflammation of microglia an abundant cell type that plays an important supporting role in the brain does not appear to be associated with dementia in Alzheimer's disease.

The finding supports recent clinical trial results that indicate anti-inflammatory drugs are not effective at fighting dementia in patients with Alzheimer's disease, which affects about 5.3 million Americans.

"For almost 20 years now, it's been claimed that brain inflammation contributes to the development of Alzheimer's disease dementia, and based on that claim, numerous clinical trials with anti-inflammatory drugs have been conducted. They have been unsuccessful," said Wolfgang Streit, Ph.D., a professor of neuroscience at the College of Medicine. "In the current paper we have shown that the brain's immune system, made up of microglia, is not activated in the brains of Alzheimer's patients, as would be the case if there were inflammation. Instead, microglia are degenerating. We claim that a loss of microglial cells contributes to the loss of neurons, and thus to the development of dementia."

Microglial cells are a subset of a very large population of brain cells known as glial cells. Neurons are the workhorse cells of the brain, enabling thought and movement, but glia are their faithful sidekicks, providing physical and nutritional support.

Glial cells, which outnumber neurons 10-to-1, are at the heart of a popular explanation for Alzheimer's disease that suggests protein fragments called beta amyloid Abeta for short clump together in the spaces between brain cells, causing memory loss and dementia. Inflammation theories suggest that microglia become "activated" and mount an immune response to these protein clumps, and instead of being helpful, a toxic release of chemicals occurs, worsening the disease effects.

However, Streit's high-resolution observations did not find evidence that Abeta activates, or inflames, human microglia cells. Nor did researchers find evidence that inflammation is to blame for brain cell death.

"This paper potentially represents a paradigm shift in the way we look at Alzheimer's disease," said Mark A. Smith, Ph.D., a professor of pathology at Case Western Reserve University and editor-in-chief of the Journal of Alzheimer's Disease. "The study goes against the very popular idea of neuro-inflammation; instead, the idea that microglia are senescent is consistent with a number of features of the disease.

"The research makes a very good case that these cells are subject to aging," said Smith, who did not participate in the study. "These cells were thought to be activated (against Alzheimer's), but this paper makes a strong case that they are not. The study has taken a novel approach that has led to a novel insight."

Using a commercially available antibody, Streit for the first time created a marker for microglial cells in human brain specimens that had been in chemical storage. The specimens were from 19 people with varying degrees of Alzheimer's, ranging from severe to none at all. Two of the samples were from Down syndrome patients, who are known to develop Alzheimer's pathology in middle age.

When researchers examined these cells alongside neurons under a high-resolution microscope, they found that unless an infection had occurred elsewhere in the body microglial cells from Alzheimer's patients were not distinctly larger or unusually shaped, which would have been the case had they been inflamed.

"What I expected to see is activated microglia right next to dying neurons," Streit said. "That is what I did not find. What I propose is glia are dying, and the neurons lose support. We now need to find out what caused glia to degenerate. Rather than trying to find ways to inhibit microglia with anti-inflammatory drugs, we need to find ways to keep them alive and strong. It's a whole new field."

The microglial cells had a tangled, fragmented appearance, similar to neurons in the throes of Alzheimer's disease or old age.

"These cells are breaking into pieces," said Streit, who collaborated with Alzheimer's researcher Heiko Braak, M.D, of the Institute for Clinical Neuroanatomy in Frankfurt. "They are on their way out. For the first time, we are proving that microglial cells are subject to aging and may undergo degeneration, and that the loss of these cells precedes the loss of neurons. Research has been so focused on finding activated microglia, no one considered that these cells were degenerating and neurons lost support."


Contact: April Frawley Birdwell
University of Florida

Related medicine news :

1. HSA Plans Gain Popularity as Premium Costs Rise
2. Study Rates Heart Health of Popular Diet Plans
3. Banco Popular Commits To Make A Difference Day 2007
4. Giant Eagle Expands Popular Generic Prescription Program and Now Offers 400 for $4
5. One-Third of Popular Songs Refer to Substance Abuse
6. Will Lipodissolve Continue to Remain Popular?
7. Climate change, gender differences, health among EurekAlert! 10 Most Popular Stories in 2007
8. Popular osteoporosis drugs triple risk of bone necrosis
9. Jan Marini Skin Research Suspends Sales of Popular Eyelash Products
10. Popular arthritis drug may disrupt heart rhythm, UB research finds
11. PetFirst: Pet Insurance To Be More Popular in 2008
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... at the 7th Annual 2015 Golden Bridge Business Awards under the New Products ... a zero capex web based sample management software that helps labs ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the ... North America Annual Meeting from November 29 to December 4, 2015. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... Francisco, CA (PRWEB) , ... December 01, 2015 ... ... Behavioral Health Center of Excellence (BHCOE) today announced that the organization has awarded ... in San Francisco, with a Distinguished Award. The award celebrates exceptional special needs ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Building on ... Johnson & Johnson (NYSE: JNJ ) today ... Pharmaceutical Companies to significantly reduce the burden of ... up 74 percent of new HIV infections among ... World AIDS Day, these new initiatives include collaborations ...
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... today that the company will present at the LD Micro ... the Luxe Sunset Boulevard Hotel in Los Angeles, ... Therapeutics, will present on Thursday, December 3, at 9:00 am ... Please register at least 10 minutes prior to the start ...
Breaking Medicine Technology: